APstem Therapeutics, Inc.

What APstem Therapeutics, Inc. does

APstem Therapeutics, Inc. is a preclinical-stage biotechnology company developing first-in-class regenerative cell therapies based on its proprietary Guide-Integrated Adult Stem Cells (giaSCs), also known clinically as APSCs. The company's platform is built on a Stanford University-licensed discovery of a naturally circulating pluripotent stem cell in adult human blood that can be activated in vitro without genetic reprogramming, embryonic material, or tumorigenic risk. giaSCs are produced by fusing immunoregulatory "guide cells" with mesenchymal stromal cells from healthy donors, yielding an allogeneic, off-the-shelf cell product with dual regenerative and immunomodulatory mechanism of action. Lead candidate AP-Skin-01 targets diabetic ulcers and has completed FDA INTERACT (2020) and pre-IND (2023) meetings; the broader pipeline addresses Type 1 Diabetes, Inflammatory Bowel Disease, and Multiple Sclerosis.

The company is headquartered in Fremont, California, employs 1-10 people, and operates as a privately held, venture-backed entity. Total disclosed funding is approximately $4.3M across three rounds (2018-2020), with investors including Magic Capital, Beyond Ventures, Oriza Ventures, InnoSpring Seed Fund, and StartX. Leadership combines Stanford-originated scientific founders (Dr. Min Hu, CEO; Dr. Shaowei Li, CSO) with biotech operator Jeffrey Cleland as Chairman, supported by an advisory bench spanning cell/gene therapy, diabetes islet transplantation, endocrinology, and wound care. APstem's commercial model, once products reach market, will rely on sale of allogeneic cell therapy products to healthcare institutions and specialty clinics; no commercial revenue currently exists. Marketing and visibility efforts center on peer-reviewed publications (PNAS, Advances in Wound Care, Stem Cell Translational Medicine), international scientific conferences (ISSCR 2019, 2024; Milan 2025), and regulatory engagement.

Name

APstem Therapeutics, Inc.

Legal name

APstem Therapeutics, Inc.

Website

https://apstemtx.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

APstem Therapeutics is a preclinical-stage biotech developing first-in-class allogeneic stem cell therapies (giaSCs/APSCs) — discovered at Stanford — that target chronic autoimmune and degenerative diseases starting with diabetic ulcers and Type 1 Diabetes.

Ownership category

akta.pro rank

Product category

Regenerative Cell Therapy Biotechnology

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Stem Cell–Based Regenerative Therapies (HLAAAGAA)

akta.pro secondary industries

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)

Keywords

• Regenerative cell therapy
• Allogeneic stem cells
• Diabetic ulcer treatment
• Type 1 Diabetes therapy
• Autoimmune disease biotechnology

Headquarters

HQ city

Fremont

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

1. Allogeneic Cell Therapy Products: APstem is developing off-the-shelf allogeneic cell therapy products (AP-Skin-01 for diabetic ulcers, APSC-based therapies for Type 1 Diabetes) that would be commercialized through healthcare institutions. The company operates at preclinical/clinical stage with no current commercial revenue.

Go-to-market motion1 record

Marketing channels4 records

Core offering

APstem Therapeutics is developing first-in-class allogeneic regenerative cell therapies based on its proprietary Guide-Integrated Adult Stem Cells (giaSCs/APSCs) platform, exclusively licensed from Stanford University. The platform enables naturally pluripotent stem cell activation in vitro without genetic reprogramming, with lead candidate AP-Skin-01 for diabetic ulcers (pre-IND completed) and pipeline indications in Type 1 Diabetes, IBD, and Multiple Sclerosis. Products are designed for off-the-shelf administration via topical, subcutaneous, or intravenous routes.

Product overview

APstem Therapeutics is developing a first-in-class regenerative cell therapy platform based on its proprietary Guide-Integrated Adult Stem Cells (giaSCs), also known in clinical form as APSCs. This technology represents a breakthrough in natural pluripotency—achieving pluripotency naturally, safely, and scalably without reprogramming, without tumorigenic risk, and without ethical barriers. The platform addresses multiple therapeutic areas including Type 1 Diabetes Mellitus (T1D), Inflammatory Bowel Disease (IBD), Multiple Sclerosis, and chronic wounds/diabetic ulcers. The lead therapeutic product, AP-Skin-01, is an 'off-the-shelf' allogeneic stem cell product for diabetic ulcers that has completed FDA pre-IND engagement. APSCs can be administered topically, subcutaneously, or intravenously, offering flexibility across therapeutic applications.

Differentiator

Problem solved

Functional benefit

Brands

• APSCs: Guide-Integrated Adult Stem Cells (giaSCs) also known in clinical form as APSCs - the company's proprietary stem cell platform for regenerative cell therapy

Products and services

• Guide-Integrated Adult Stem Cells (giaSCs/APSCs) Platform Proprietary stem cell platform derived through a process that fuses immunoregulatory 'guide cells' with mesenchymal stromal cells from healthy human donors, creating a highly regenerative, immunomodulatory cell type with superior therapeutic potential and safety for treating chronic diseases.
• AP-Skin-01 Off-the-shelf allogeneic stem cell product developed for the treatment of diabetic ulcers and chronic wounds, with FDA pre-IND engagement completed.

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Stanford UniversitycoreStrategic or Co-development PartnerCore intellectual property exclusively licensed from Stanford University. APstem was founded on breakthrough discovery of adult stem cells derived from mouse peripheral blood with technology developed at Stanford. The company subsequently established human Guide-Integrated Adult Stem Cells (giaSCs) under this licensing arrangement.
• StartXminorOthersAPstem Therapeutics is a proud member of the StartX community - a Stanford alumni network of scientists and physicians supporting biotech innovation. Company participated in StartX Med COVID-19 Task Force in 2020.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Vertex Pharmaceuticals: Vertex is developing VX-880 (zimislecel), an allogeneic stem cell-derived islet cell therapy for Type 1 Diabetes, and acquired ViaCyte in 2022. It is the most direct and well-capitalized competitor pursuing curative cell therapy for T1D, the same primary indication APstem targets.
• ViaCyte (acquired by Vertex): ViaCyte developed PEC-Direct and VC-02, stem cell-derived pancreatic progenitor cell therapies for T1D, and is now part of Vertex. Comparable to APstem's lead T1D indication and allogeneic off-the-shelf approach.
• Semma Therapeutics / Vertex VX-264: Vertex's VX-264 program encapsulates stem cell-derived islet cells for T1D, addressing immune rejection without immunosuppression—a parallel approach to APstem's immunomodulatory mechanism. Closely comparable in target indication and cell therapy modality.
• Mesoblast: Mesoblast commercializes remestemcel-L, an allogeneic mesenchymal stem cell therapy, and is advancing MSC-based therapies across inflammatory and immune-mediated conditions (GvHD, IBD, MS). Directly comparable in MSC-derived allogeneic cell therapy approach and immunomodulatory mechanism.
• BlueRock Therapeutics (Bayer): BlueRock (acquired by Bayer for up to $1B) is developing iPSC-derived cell therapies with a focus on cardiac and neurological indications. Comparable in pluripotent stem cell modality, allogeneic approach, and regenerative medicine positioning.
• Fate Therapeutics: Fate Therapeutics develops iPSC-derived NK and T-cell cancer immunotherapies using a multiplexed engineering platform. Comparable as an iPSC-derived cell therapy developer pursuing allogeneic off-the-shelf products with engineered cellular functionality.
• Sana Biotechnology: Sana Biotechnology develops engineered cell therapies (iPSC-derived, hypoimmune) for cancer and autoimmune diseases. Comparable in stem cell-derived therapy modality and pursuit of immune evasion strategies relevant to T1D and other autoimmune indications.

Emerging players

• Pluristem Therapeutics: Pluristem develops placenta-derived MSC-like adherent stromal cell therapies for inflammatory and ischemic conditions, including peripheral artery disease and wound healing. Comparable in allogeneic MSC-derived regenerative cell therapy approach.
• Cynata Therapeutics: Cynata is developing CYP-001, an iPSC-derived MSC product for GvHD and osteoarthritis, using a manufacturing platform that enables scalable allogeneic MSC production. Comparable in scalable MSC-derived allogeneic cell therapy approach and immunomodulatory indications.
• Sigilon Therapeutics: Sigilon developed encapsulated cell therapies (e.g., SIG-001 for hemophilia A) using allogeneic cells in immune-protective spheres. Comparable in allogeneic engineered cell therapy approach and pursuit of indications requiring reduced/no immunosuppression.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about APstem Therapeutics, Inc.